By InvitationPhase 4

Vevye + Flarex Combination Therapy for Dry Eye

United States60 participantsStarted 2026-04-03

Plain-language summary

This study evaluates the safety and efficacy of combination therapy with Vevye (cyclosporine ophthalmic solution) and Flarex (fluorometholone acetate ophthalmic suspension) in adults with moderate to severe dry eye disease. Participants receive Vevye twice daily and Flarex four times daily, with outcomes assessed over a 1-month period.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria:Adults ≥18 years VAS ≥30 mm (moderate-severe dry eye) Able to provide informed consent Women of childbearing potential must meet contraception requirements \- Exclusion Criteria: * Uncontrolled systemic disease Ocular surgery/trauma within 12 months Punctal plugs \<6 months Active ocular infection/inflammation Recent lid heating therapy (\<6 months) Pregnant or breastfeeding Use of topical ocular meds after screening Significant corneal disease Systemic meds causing dry eye (e.g., antihistamines, antidepressants) Intraocular pressure \>21 mmHg or glaucoma history Contact lens use within 7 days Substance abuse within 12 months

What they're measuring

VAS

Timeframe: Baseline to 1 Month

Trial details

NCT IDNCT07553455

SponsorCanyon City Eyecare

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Dry Eye trials